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Using common variants to indicate cancer genes
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The catalogue of tumour-specific somatic mutations (SMs) is growing rapidly owing to the advent of next-generation sequenc-
ing. Identifying those mutations responsible for the development and progression of the disease, so-called driver mutations,
will increase our understanding of carcinogenesis and provide candidates for targeted therapeutics. The phenotypic conse-
quence(s) of driver mutations cause them to be selected for within the tumour environment, such that many approaches
aimed at distinguishing drivers are based on finding significantly somatically mutated genes. Currently, these methods are
designed to analyse, or be specifically applied to, nonsynonymous mutations: those that alter an encoded protein. However,
growing evidence suggests the involvement of noncoding transcripts in carcinogenesis, mutations in which may also be
disease-driving. We wished to test the hypothesis that common DNA variation rates within humans can be used as a baseline
from which to score the rate of SMs, irrespective of coding capacity. We preliminarily tested this by applying it to a dataset of
159,498 SMs and using the results to rank genes. This resulted in significant enrichment of known cancer genes, indicating
that the approach has merit. As additional data from cancer sequencing studies are made publicly available, this approach
can be refined and applied to specific cancer subtypes. We named this preliminary version of our approach PRISMAD (poly-
morphism rates indicate somatic mutations as drivers) and have made it publicly accessible, with scripts, via a link at
www.precancer.leeds.ac.uk/software-and-datasets.
Cancer develops via the accumulation of somatic mutations
(SMs), some of which confer a selective advantage to the
tumour, enabling it to proliferate abnormally. Distinguishing
such driver mutations, which highlight candidate genes for
targeted therapeutics, from passenger mutations (nonpatho-
logical by-products of the underlying mutagenic process) is
an important task. Two main approaches exist: (i) prioritise
mutations predicted to detrimentally affect an encoded pro-
tein1 and (ii) identify genes repeatedly mutated within, or
across, cancer subtypes.2 The latter results from the hypothe-
sis that SMs in genes causally associated with cancer undergo
positive selection in tumours, occurring more often than
expected by chance. Scoring this requires determination of
the background mutation rate (BMR), given the commonly
hypermutated state of cancer genomes, from which to mea-
sure the signiﬁcance of the mutation count in a given gene.
Often the rate of synonymous SMs, scaled by the ratio of
potential nonsynonymous:synonymous mutations, is used,
under the assumption that synonymous mutations are selec-
tively neutral (i.e., phenotypically silent).2 This is ﬂawed: (i)
it restricts analysis to protein-coding genes and (ii) the
assumption of selective neutrality is increasingly hard to jus-
tify owing to the prevalence of functional noncoding tran-
scripts. Nonprotein coding genes include microRNAs
(miRNAs), long intergenic noncoding RNAs (lincRNAs) and
pseudogenes, all shown to have causal associations with vari-
ous cancers.3 The functionality of these transcripts results
directly from nucleotide sequence, rather than encoded
amino acids, based on binding other nucleotides or proteins
in a sequence-speciﬁc manner.4 Genetic variation within non-
coding transcripts will, therefore, alter their functionality with
potential phenotypic consequences, but the notion of nonsy-
nonymous and synonymous variation does not apply. Addi-
tionally, synonymous mutations in protein-coding genes can
exert a phenotypic effect by altering the resulting mRNA’s
ability to (i) interact with regulatory noncoding RNAs or (ii)
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fold stably, directly affecting translation.5 We hypothesise
that the amount of variation observed within a transcript in
nondiseased tissue is a measure of that transcript’s tolerance
to mutation, and that if the number of observed tumour-
speciﬁc mutations exceeds this level it suggests positive selec-
tion in the tumour and a possible role for that transcript in
carcinogenesis. This hypothesis is best tested in a tissue-
speciﬁc manner, as mutational signatures in cancer vary by
subtype owing to different mutagen exposure and disease
processes.6 However, this requires a database of known SMs
in nondiseased tissue of origin of the cancer in question.
Such a database does not currently exist as blood is most
commonly used as the matched normal for genomic sequenc-
ing. However, these data will likely be available in future
owing to RNA sequencing, which often includes a matched
nondiseased tissue of origin to provide an expression
baseline.
As the most ideal datasets for testing our hypothesis are not
available, we opted to investigate whether the rate of common
human germline variation [i.e., the common polymorphism
(CP) rate] could provide an alternative BMR for scoring SM
rates in cancer genomes. Most oncogenes and tumour suppres-
sor genes are highly conserved within mammals, indicating the
important physiological roles of those genes. Similarly, non-
coding regions from which functional transcripts are tran-
scribed are often conserved.7 A single mutation within any
evolutionary constrained region could be responsible for detri-
mental phenotypic changes and is, therefore, unlikely to be
commonly observed within the human germline. Our adapted
hypothesis is that any genomic region in tumours that har-
bours SMs more often, relatively, than it harbours CPs is a can-
didate for carcinogenesis. To test this, we ascertained the CP
rate within humans and compared it to the SM rate, using
tumour-speciﬁc SMs identiﬁed from sequencing studies.
Material and Methods
Genome annotation
Annotations for human reference genome GRCh37 were
downloaded from GENCODE148 and transcript records
merged, via a bespoke perl script, creating a single annotation
per gene ID with nonredundant exons delineated.
Population data
A bespoke script (available online) accessed Ensembl69,9 via
its perl programming interface, and extracted the total num-
ber of basepairs, and the number of commonly polymorphic
loci, within each exon. A commonly polymorphic locus is a
variant position sequenced in germline samples at least 20
times with a minor allele frequency of 5–50% (see Supporting
Information for justiﬁcation of the chosen allele frequency).
The rate (commonly polymorphic alleles per kilobase) is cal-
culated and output per gene. Ensembl69 contained informa-
tion from dbSNP137, including all data from the 1000
Genomes Project phase 1 and HapMap phase 3.
Somatic mutations
We use SM to mean a tumour-speciﬁc substitution or indel
involving less than 500 bp. Genome coordinates were con-
verted, where necessary, to GRCh37 using the University of
California, Santa Cruz (UCSC) liftOver tool. SMs were down-
loaded from catalogue of somatic mutations in cancer (COS-
MIC)62 via Biomart or extracted from Supporting Information
in additional publications (with no study overlap).10 All COS-
MIC SMs were validated from primary tumours and identiﬁed
using whole genome sequencing. All manually extracted data
were from whole genome or exome sequencing studies only.
Supporting Information Table 1 outlines all references for the
SMs collated. A bespoke perl script (available online) was used
to ascertain the SM rate using our amended genome annota-
tion ﬁles. Analysis was restricted to exon regions.
Statistical analysis
CP and SM rates were analysed in R. Attempts to ascertain
the best way to amalgamate the CP rate and SM rate infor-
mation into a single metric are given in Supporting Informa-
tion. Functional analysis was performed using the DAVID
Bioinformatics Resources, release 6.7.11 Statistical tests were
performed in R.
Comparison with other programmes
The Supporting Information contains information on a com-
parison between PRISMAD (polymorphism rates indicate
somatic mutations as drivers) and another programme that is
applicable to noncoding regions.
miRNA folding predictions
The fasta sequence for the wild-type and mutant miRNA
precursor, hsa-mir-99b, were input to RNAfold.12 Resulting
predictions are those according to the minimum free energy
and partition function. Free energy values were output for
What’s new?
Somatic mutations are important drivers of the cancerous process but identifying the key “driver” mutations remains a challeng-
ing question. The authors hypothesize that the variation level in healthy tissue represents a transcript’s tolerance to mutation
and that if the number of mutations in tumors exceeds this level, positive selection might have occurred that point to this tran-
script as a major driver in carcinogenesis. They tested their program with a large dataset of somatic mutations and obtained a
ranked list of genes significantly enriched in known cancer-associated genes. Their program called PRISMAD is publicly available
and could help identify new driver mutations in various tumors.
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each structure and used to ascertain the change between
wild-type and mutated sequences.
PRISMAD web server
The web server was written in PHP and html.
Results
We deﬁne a CP as one with a minor allele frequency of at
least 5% at a locus genotyped at least 20 times. This thresh-
old performed best amongst those tested (Supporting Infor-
mation). The CP rate per gene is the number of exonic CPs
divided by the number of exonic kilobases. Using genome
annotation ﬁles, we separated genes into functional classes:
protein-coding, antisense, long-intergenic noncoding
(linc)RNA, long noncoding (lnc)RNA, micro (mi)RNA and
pseudogene. The lncRNAs are distinct from lincRNAs in that
they are located within genes; they are on the sense strand,
making them distinct, also, from antisense genes.
Inspecting rates of variation in cancer genes
We hypothesise that germline mutations in cancer-associated
genes are more likely to be phenotypically detrimental (owing
to effects at the RNA as well as protein level) and are, thus,
more likely to be selected against leading to a reduced CP
rate in cancer-associated genes compared with noncancer-
associated genes. This is similar to the notion that driver
SMs will undergo positive selection within the tumour lead-
ing to a higher SM rate in cancer-associated genes compared
with noncancer-associated genes in the tumour. To test this
we ascertained the list of 483 known, protein-coding cancer
genes from the Cancer Gene Census.13 The median CP rate
was 1.21 CP/kb for cancer genes and 1.61 CP/kb for non-
cancer genes. In agreement with our hypothesis, the CP rate
for cancer genes was signiﬁcantly lower (Wilcoxon, p: 1.28 3
10212). The median SM rate was 0.40 SM/kb for cancer
genes and 0.31 SM/kb for noncancer genes. As expected the
SM rate is signiﬁcantly higher in cancer genes (Wilcoxon, p:
1.63 3 1025) but, interestingly, the effect size is not as large
as for CP rate. We wished to use this information to rank
somatically mutated genes with respect to the likelihood that
they are causally associated with cancer. We attempted sev-
eral statistical modelling approaches (Supporting Informa-
tion), concluding that the best results were obtained using
created a metric we called the rate difference (RD), obtained
by subtracting the CP rate from the SM rate:
RD5SM rate2CP rate : (1)
The median RD for cancer genes was 20.83 variants/kb
and for noncancer genes 21.17 variants/kb. The RD is signif-
icantly higher for cancer genes and the effect is greater than
that of both SM rate and CP rate in isolation (Wilcoxon,
p: 1.04 3 10214).
Using RD to rank genes, genome-wide
Our approach is applicable genome-wide as it uses the CP
rate, which can be ascertained for any given genomic region,
as a baseline for interpreting SM rates. We calculated the RD
for each of 20,036 protein-coding genes, 6,296 lincRNAs,
3,110 miRNAs, 786 lncRNAs and 13,004 pseudogenes (Table
1 and Supporting Information Tables 2 and 3). The top
1,000 protein-coding genes (ca. 5%), ranked by descending
RD, included signiﬁcantly more known cancer genes than
expected by chance (v2, p: 0.00028), whereas the top 1,000
ranked by descending SM rate did not (v2, p: 0.38). This
indicates that RD is a more powerful predictor than SM rate
alone. This enrichment was not observed if the datasets were
separated into synonymous and nonsynonymous variants (v2,
p> 0.01, Supporting Information).
Functional analysis of the top 1,000 protein-coding genes
according to RD revealed signiﬁcant enrichment in the path-
ways of cadherin signalling (PANTHER P00012, adjusted
p< 0.05) in which 21 members were highlighted (Supporting
Information Table 4), and Wnt signalling (PANTHER
P00057, adjusted p< 0.05), with 34 members highlighted
(Supporting Information Table 5).
The top-ranking noncoding transcripts mostly lacked a
single exonic CP, with only 76 containing more than one SM
(Supporting Information Table 3). Literature searches
revealed a dearth of information regarding the functionality
of the top-ranking noncoding transcripts according to RD
except in the case of MIR99B. This is a miRNA with an RD
of 14.5 variant/kb owing to an SM identiﬁed in a gastric
tumour.14 The MIR99B gene produces two mature miRNAs
(hsa-miR-99b-3p and hsa-miR-99b-5p); the dysregulation of
both has been associated with carcinogenesis.15 Mutations
within miRNAs can have causal associations with cancer.16
The SM, NC_000019.9:g.52195904G>A, highlighted by our
approach resides within a predicted base-paired portion of
the hsa-mir-99b precursor hairpin from which the two
mature miRNAs are excised (Fig. 1a). The mutation is pre-
dicted to alter precursor folding in such a way that removes
local base pairing and causes a predicted reduction in folding
stability by 1.24 kcal/mol program (Fig. 1b). This altered con-
ﬁguration and change in stability could alter the processing
of the hairpin, required to excise the mature miRNAs.
Table 1. Highlighting genes that contain candidate somatic driver
mutations in different functional classes
Class of gene Total
Mean RD
(variants/kb)
Median RD
(variants/kb)
Protein-coding 20,036 21.49 21.16
lincRNA 6,296 22.80 22.24
miRNA 3,110 22.67 0
lncRNA 786 22.43 21.96
Pseudogene 13,004 22.69 21.83
RD: rate difference (somatic mutation rate minus common polymor-
phism rate).
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Discussion
Machine learning methods that identify disease-causing nonsy-
nonymous mutations reveal that evolutionary conservation is
an, if not the most, important predictor variable.1,17 This is
because genetic variants that detrimentally alter the function of
an encoded protein undergo negative selection throughout
evolution. It follows that genetic variation that detrimentally
alters the noncoding function of a transcript will also undergo
negative selection. We tested the hypothesis that the number of
commonly occurring germline polymorphisms within a
genomic region (protein coding and/or noncoding) can be
used as a BMR from which to score SM rates in tumours and
identify potential cancer-driving genes. In support of this
theory, exonic SNP density (number of polymorphic loci) is
one of the most informative predictive features in a machine-
learning tool to predict cancer-driving mutations.1 We devel-
oped a parsimonious method for ranking genes/genomic
regions using the RD [Eq. (1)]. Our method is not restricted to
protein-coding regions and makes no prior assumptions
regarding which mutations are phenotypically silent.
General cancer pathways
The top ranked genes highlighted by PRISMAD were
enriched for Wnt signalling and cadherin signalling path-
ways. Wnt signalling is involved in cell–cell communication
and its study is becoming increasingly widespread in cancer
research.18 Similarly, the role of cadherins in various types of
cancer continues to be an area of active research.19 The eluci-
dation of cancer-related pathways by our approach further
indicates its merit.
Application to noncoding genes
Attempts to investigate noncoding SMs thus far have been on
the level of speciﬁc mutations within single samples, without
reproducibility, or have been anecdotal. In those cases, though,
it has been stressed that it is likely that some drivers will lie
within noncoding regions.20,21 We applied our method to sev-
eral types of noncoding genes implicated in carcinogenesis:
lincRNAs, miRNAs, lncRNAs and pseudogenes. We revealed
few CPs in many of these genes. This is expected given that
interest in noncoding regions, and the ability to sequence them
to the required depth, has only increased in the last decade,
meaning there is a dearth of information on variation rates
therein. The 1000 genomes pilot constituted whole genome
sequencing, but thereafter the project focused on protein-
coding regions.22We believe that although economically under-
standable, negation of noncoding regions may be detrimental
to cancer research. Many whole genomes have been sequenced,
with SM data deposited in relevant databases. Similar deposi-
tion of genome-wide germline variants into dbSNP would facil-
itate the creation and use of approaches such as ours.
Our approach is to highlight some noncoding genes as
potentially harbouring driver SMs, but a lack of functional
information makes these difﬁcult to verify. Rather, we hope
that validating our approach in protein-coding genes suggests
the noncoding genes highlighted are worthy of prioritisation
or, at least, when additional noncoding germline variation is
present in online databases, ours is an approach worth apply-
ing. We highlighted one known cancer-associated miRNA
gene, MIR99B, using PRISMAD, and predicted how the SM
identiﬁed within it may result in altered processing and
expression of two mature miRNAs.
Many methods exist to speciﬁcally identify nonsynony-
mous cancer-driving mutations. Our approach can be used
alongside these, potentially highlighting distinct genes, but we
do not propose our method replace them if the goal is to
highlight nonsynonymous variants.
It has recently been shown that additional factors, i.e.,
gene expression level and stage of replication, affect the num-
ber of tumour-speciﬁc SMs that a gene acquires, irrespective
of involvement in carcinogenesis.23 This is thought to result
from DNA repair and replication effects: genes expressed at
Figure 1. Predicted folding of the hsa-mir-99b precursor in wild-
type (a) and somatically mutated (b) form. The locations of the
mature miRNAs (had-miR-99b-3p and had-miR-99b-5p) that are
excised from the precursor are annotated. The colouring indicates
the probability of base pairing as indicated by the scale bar. The
location of the variant position is given by the block arrow, with
the change in the mutant sequence labelled on the figure. [Color
figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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low levels are less exposed to transcription-coupled repair,
and those replicating late succumb to error owing to a reduc-
tion in the concentration of free nucleotides within the cell.
These factors will equally affect mutation rates in noncancer
cells, though to a lesser degree because these cells are not
aberrantly proliferating. Our original hypothesis better incor-
porates these recent ﬁndings: an RD calculated from com-
monly polymorphic sites speciﬁcally within matched normal
tissue (which will include germline and nondiseased tissue
SMs) to the tumour in question will factor in the aforemen-
tioned biases, assuming that expression proﬁles and replica-
tion timing of such cells are similar to the cancer cells that
originated from them. Unfortunately, there is currently insuf-
ﬁcient publicly available appropriate sequencing data to test
this extended hypothesis, but it provides an avenue for future
research.
Whilst this manuscript was under review, an article indi-
cating how patterns of polymorphisms within noncoding
regions can be used as a basis for identifying cancer-driving
SMs has been published in Science.24 The authors describe a
method that can be used in conjunction with ours: FunSeq.
This approach ﬁlters out germline polymorphisms and then
prioritises variants according to their location in conserved
regions, binding motifs and (for protein-coding genes) hubs
of gene networks. This work further highlights that, as the
number of tumour-speciﬁc SMs increases, approaches aimed
at scoring variation in noncoding regions are sorely needed.
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